In Brief
Bispecific antibodies reveal the presence and function of heterotypic ubiquitin chains containing K11 and K48 linkages in cell-cycle regulation and protein quality control.
INTRODUCTION
Posttranslational modification with the highly conserved and essential protein ubiquitin controls cell division, differentiation, and survival in all eukaryotes (Harper and Bennett, 2016; Husnjak and Dikic, 2012; Ravid and Hochstrasser, 2008; Skaar et al., 2013; Yau and Rape, 2016) . The precision and versatility of ubiquitylation in signal transduction depends on the ability of cells to assemble multiple conjugates with distinct topologies and functions. Attachment of a single ubiquitin, referred to as monoubiquitylation, typically alters a target's interaction landscape (Husnjak and Dikic, 2012) . In addition, cells can assemble polymeric ubiquitin chains, in which subunits are connected through an isopeptide bond between eight possible attachments sites on one ubiquitin and the C terminus of the next. Homotypic chains are characterized by a single predominant linkage, as in K11-and K48-linked polymers that promote proteasomal degradation (Chau et al., 1989; Jin et al., 2008) , or M1-and K63-linked conjugates that coordinate the reversible assembly of signaling complexes (Spence et al., 1995; Tokunaga et al., 2009; Wang et al., 2001) . By contrast, heterotypic ubiquitin chains contain multiple linkages and adopt mixed or branched topology (Yau and Rape, 2016) . The signature motifs of branched chains are ubiquitin molecules that are modified on two or more residues at the same time.
Linkage-specific antibodies and mass spectrometry provide powerful approaches to study homotypic ubiquitylation at the physiological level (Matsumoto et al., 2010 (Matsumoto et al., , 2012 Newton et al., 2008; Xu et al., 2009) . By contrast, the analysis of heterotypic chain types has relied entirely on indirect means, such as in vitro reconstitution, treatment of purified chains with deubiquitylases, or expression of engineered ubiquitin variants. Such experiments suggested that M1/K63-linked chains control nuclear factor kB (NF-kB) transcription factor activation (Emmerich et al., 2013 (Emmerich et al., , 2016 Wertz et al., 2015) , while K11/K48-branched chains signal the degradation of cell-cycle regulators during mitosis (Meyer and Rape, 2014) . Similar in vitro or protein engineering evidence exists for K48/K63-branched, K29/K48-linked, or more complex heterotypic chains (Kim et al., 2007; Koegl et al., 1999; Kristariyanto et al., 2015; Liu et al., 2017; Ohtake et al., 2016) . These findings implied that cells use heterotypic chains for signal transduction, yet, without a method to monitor endogenous polymers in vivo, the abundance, function, and importance of mixed or branched ubiquitin chains remain very poorly understood.
Synthesis of ubiquitin chains requires the coordinated action of E1 activating enzymes, E2-conjugating enzymes, and E3 ligases (Komander and Rape, 2012) . Most E3 ligases use dedicated domains to recruit specific substrates, while they determine the linkage specificity of chain formation dependent on their catalytic module: members of the homologous to E6AP C terminus (HECT) or RING-in between-RING (RBR) families of E3s, which contain an active site cysteine charged with ubiquitin, directly select the ubiquitin residue for chain elongation (Kamadurai et al., 2009; Kim and Huibregtse, 2009) . By contrast, RING-E3s help transfer ubiquitin from the active site of an E2 to target lysine residues and rely on their E2s to establish chain topology (Plechanovová et al., 2012; Wickliffe et al., 2011) . The human genome contains 600 E3s, several of which are encoded by essential genes or mutated in tumorigenesis, neurodegeneration, and developmental diseases (Deshaies and Joazeiro, 2009; Lipkowitz and Weissman, 2011; Rotin and Kumar, 2009 ). However, even in vitro few E3 ligases are known to synthesize mixed or branched polymers, and mechanisms of heterotypic chain production are not understood. The impact of heterotypic chains on signal transduction is therefore not known, and many pathways that depend on these conjugates likely await discovery.
To address these issues, we developed a bispecific antibody that allowed us to identify mitotic regulators, misfolded nascent polypeptides, and pathological Huntingtin as physiological substrates of branched ubiquitin chains containing both K11 and K48 linkages. We found that K11/K48-branched polymers ensure rapid substrate delivery to the proteasome, which prevents accumulation of aggregation-prone nascent proteins. Our findings place K11/K48-linked chains at the heart of cell-cycle and protein quality control, two essential pathways that rely on rapid and efficient protein degradation. Consistent with this notion, we show that enzymes and effectors of K11/K48-linked chains are encoded by essential genes and mutated across neurodegenerative diseases. Our work establishes that endogenous heterotypic ubiquitin chains play important roles in cellular signaling pathways.
RESULTS

A K11/K48-Bispecific Antibody Recognizes Heterotypic Ubiquitin Chains
Starting with K11-and K48-monospecific antibodies (Matsumoto et al., 2010; Newton et al., 2008) , we used knobs-into-holes heterodimerization technology (Merchant et al., 1998) to create a bispecific antibody, in which one arm recognizes the K11-ubiquitin linkage and the other binds the K48 linkage (Figures 1A and S1A) . As controls, we engineered K11/gD and K48/gD antibodies that pair a ubiquitin-directed antibody arm with one that detects an unrelated viral protein ( Figure 1A ). We purified these antibodies to homogeneity and characterized them by SDS-PAGE, analytical size-exclusion chromatography, multi-angle light scattering, and mass spectrometry (Figures 1B, S1B-S1D, and S2A-S2C; Tables S1 and S2). This validation confirmed that we had engineered and purified well-behaved antibody species.
We used surface plasmon resonance (SPR) to assess the specificity of these antibodies toward K11/K48-branched ubiquitin trimers. At high densities of immobilized trimer (700 response units [RUs] ), the K11/K48-bispecific antibody showed 500-to 1,000-fold higher affinity for K11/K48-branched ubiquitin than K11/gD and K48/gD antibodies (Tables S3 and S4 ; Figure S1H) . By contrast, K11/K11-or K48/K48-monospecific antibodies bound K11/K48-branched trimers with a similar affinity as the bispecific antibody, suggesting that they recognize their linkage independently of branching. At lower immobilization densities (150 RUs), the bispecific antibody displayed a slightly reduced affinity toward K11/K48-branched trimers, while the affinity of the control antibodies was unchanged. This indicated that the K11/K48-bispecific antibody acts as a coincidence detector that gains avidity from simultaneous detection of K11 and K48 linkages. In agreement with this notion, the K11/K48-bispecific antibody was able to detect a 1:1 mixture of immobilized K11-and K48-linked dimers, which mimics the proximity of these linkages in branched ubiquitin molecules, while it showed a similar low affinity to homotypic K11-or K48-linked dimers or tetramers as both control bispecific antibodies (Tables  S3 and S4) .
We next tested the ability of the K11/K48-bispecific antibody to detect branched ubiquitin conjugates in western blot analyses. Notably, while the K11/K48-bispecific antibody efficiently recognized K11/K48-branched trimers, it failed to detect monomeric or dimeric ubiquitin, including K11-or K48-linked di-ubiquitin species ( Figure 1C ). This behavior was different from K11/ K11-and K48/K48-monospecific antibodies, which bound ubiquitin dimers and trimers containing their cognate linkage, as well as from K11/gD and K48/gD control antibodies, which did not produce any signal under these conditions. The K11/K48-bispecific antibody displayed similar selectivity toward variants of branched ubiquitin: while it readily recognized K11/K48-branched trimers, it did not detect their K11/K63-, K48/K63-, or M1/K63-branched counterparts ( Figures 1D and 1E ). Using an engineered ligation system (Meyer and Rape, 2014), we found that the K11/K48-bispecific antibody recognized high-molecular-weight (MW) K11/K48-linked polymers in strong preference over homotypic K11-or K48-linked chains ( Figure 1F ). Moreover, we used radiolabeled substrates modified with high-MW K11/ K48-branched chains to quantify antibody specificity under immunoprecipitation conditions. Similar to SPR and western blot analyses, the K11/K48-bispecific antibody displayed a much higher affinity for K11/K48-branched chains than K11/gD or K48/gD control antibodies ( Figure 1G ).
The SPR analysis had indicated that the K11/K48-bispecific antibody might function as a coincidence detector that binds to both K11 and K48 linkages at the same time. Consistent with this notion, the K11/K48-bispecific antibody detected mixed trimers with proximal K11 and K48 linkages with similar efficiency as K11/K48-branched trimers ( Figure S1E ). However, the K11/K48-bispecific antibody did not recognize mixtures of separate K11-and K48-linked dimers in western blot analyses, nor did it bind mixtures of K11-and K48-linked homotypic chains ( Figures S1F and S1G) . Thus, the striking avidity gain provided by coincidence detection allows the bispecific antibody to selectively report on heterotypic K11/K48-linked chains, yet two important control experiments should be performed before conclusions about chain topology are drawn: first, as K11/gD and K48/gD antibodies have low, yet significant, affinity for their cognate linkages, both control antibodies must be implemented in western blots or quantitative mass spectrometry at the same concentration and incubation time as the K11/K48-bispecific antibody. Second, as a coincidence detector detects proximal K11 and K48 linkages, biochemical experiments should be used to distinguish between neighboring homotypic chains on the same substrate, mixed chains, or branched ubiquitin conjugates. In the remainder of this study, we demonstrate how the Figure 1 . A Bispecific Antibody Specifically Detects K11/K48-Linked Heterotypic Ubiquitin Chains (A) Overview of bispecific antibodies produced in this study, as well as established K11-and K48-monospecific antibodies (Matsumoto et al., 2010; Newton et al., 2008) . (B) Final size exclusion chromatography of K11/K48-bispecific antibody purification. (C) The K11/K48-bispecific antibody detects K11/K48-branched ubiquitin trimers. Equal levels of monomeric ubiquitin, all possible ubiquitin dimers, and K11/ K48-branched ubiquitin trimers were analyzed by Coomassie gel electrophoresis or western blots using the indicated antibodies. (D) The K11/K48-bispecific antibody detects K11/K48, but not K11/K63 or K48/K63 branches. Equal concentrations of branched ubiquitin trimers were analyzed by western blotting using the indicated antibodies at identical antibody concentrations and exposure times. (E) The K11/K48-bispecific antibody detects K11/K48-but not M1/K63-branched ubiquitin. Recombinant ubiquitin trimers were analyzed as described above. (F) The K11/K48-bispecific antibody can discriminate high-molecular-weight ubiquitin chains. An engineered ubiquitin ligation system (Meyer and Rape, 2014) using the E3 APC/C, the E2 enzymes UBE2S and/or UBE2G2 CTP , and ubiquitin was used to generate K11/K48-branched chains and homotypic K11-or K48-linked chains. Chain formation was analyzed by using the K11/K48-bispecific antibody or established monospecific antibodies that recognize the K11 or K48 linkage, respectively. Western blots were analyzed at identical antibody concentrations and exposure times (i.e., explaining the lack of signal with control antibodies). (G) The K11/K48-bispecific antibody allows for purification of K11/K48-branched chains by immunoprecipitation. K11/K48-branched ubiquitin chains were assembled on the 35 S-labeled APC/C-substrate cyclin A as described (Meyer and Rape, 2014) and conjugates were affinity-purified using identical concentrations of K11/K48, K11/gD, or K48/gD antibodies. The purified radioactivity was quantified after autoradiography; quantification is shown of three independent experiments; (n = 3; SEM). See also Figure S1 .
unique binding properties of the K11/K48-bispecific antibody can be exploited to reveal the critical role of heterotypic ubiquitin chains in cellular signaling.
The APC/C Assembles K11/K48-Branched Chains during Mitosis We first used the K11/K48-bispecific antibody to analyze the products of the anaphase-promoting complex (APC/C), an E3 that controls cell division in all eukaryotes. Previous work with ubiquitin mutants had indicated that the APC/C labels substrates with K11/K48-branched chains, but whether the APC/C produces such conjugates under physiological conditions remained unclear (Meyer and Rape, 2014) . In vitro, the APC/C-dependent synthesis of branched chains is initiated by an E2 with broader linkage specificity, such as UBE2C (Kirkpatrick et al., 2006) , whereas branching is catalyzed by the K11-and APC/C-specific E2 UBE2S (Meyer and Rape, 2014) . Consistent with these studies, the K11/K48-bispecific antibody showed that APC/C, UBE2C, and UBE2S labeled their mitotic substrate cyclin A with K11/K48-linked chains (Figures 2A and S3A ). The APC/Cdependent production of heterotypic chains required equal concentrations of UBE2C and UBE2S, a condition that is specifically encountered during mitosis (Rape and Kirschner, 2004; Williamson et al., 2009 ). Similar observations were made using a different substrate, securin ( Figure S3B ), or a distinct initiating E2, UBE2D3 ( Figure S3C ). To assess the ubiquitin chain topology assembled by the APC/C, we performed in vitro reactions with mixtures of ubiquitin K11R Figure 2 . The APC/C Assembles Heterotypic K11/K48-Linked Chains (A) The APC/C produces K11/K48-linked ubiquitin chains in vitro. APC/C purified from human mitotic cells was incubated with increasing concentrations of the initiating E2 UBE2C, constant levels of the branching E2 UBE2S, and the substrate cyclin A. Ubiquitylation of cyclin A was assessed by western blotting using the indicated antibodies. (B) K11/K48-linked chains accumulate during mitosis. HeLa cells were synchronized in prometaphase, released into cell division, and subjected to protein expression analysis at the indicated time points. Cells were either transfected with control siRNAs or validated siRNAs targeting UBE2S (Kelly et al., 2014) . (C) CDC20 and cyclin A are modified with K11/K48-branched chains in cells. Above: CDC20 peptides ubiquitylated at Lys490 were detected only in K11/K48-bispecific but not in K11/gD-or K48/gD-control affinity purifications. Other ubiquitylation sites were not detected on CDC20. Lower panel: affinity purifications of ubiquitin chains from mitotic lysates were performed with the indicated antibodies under denaturing conditions. Co-purifying endogenous CDC20 or cyclin A was detected by a specific antibody. The asterisk marks a non-specific band caused by serendipitous antibody dissociation during elution. (D) Endogenous NEK2A and cyclin A are likely modified with K11/K48-linked ubiquitin chains. Ubiquitin conjugates of different topologies were affinity-purified from mitotic HeLa cells grown either in the presence or absence of proteasome inhibitors and analyzed by western blotting using specific antibodies. The inability of the K48-specific antibody to purify NEK2A is likely caused by few K48 linkages that are buried in the branched ubiquitin conjugate (Meyer and Rape, 2014) . Endogenous cyclin A is modified with either K11/K48-linked ubiquitin chains or with distinct conjugates containing K48-, but less so K11 linkages. See also Figure S1 . and ubiquitin K48R variants. Under these conditions, the APC/C could produce proximal homotypic chains or mixed polymers, but not branched conjugates, because no ubiquitin molecule contains both K11 and K48 (Meyer and Rape, 2014) . Independently of substrate or initiating E2, the K11/K48-bispecific antibody only detected ubiquitin chains if the APC/C was incubated with wild-type ubiquitin, but not if reactions were carried out in the presence of both ubiquitin K11R and ubiquitin K48R ( Figures  S3A-S3C ). These observations provide direct evidence for the APC/C synthesizing K11/K48-branched ubiquitin chains.
Supporting these in vitro results, we found in synchronization and microscopy experiments that K11/K48-linked chains increase in abundance during mitosis, when the APC/C ubiquitylates most of its targets ( Figures 2B, S3D , and S3E). We did not detect K11/K48-linked chains in mitotic cells depleted of the APC/C-specific E2 UBE2S ( Figures 2B and S3E ), which suggests that during cell division most K11/K48-linked polymers are attached to APC/C substrates. Proteomic analyses from mitotic cells reaffirmed the role of the APC/C in the synthesis of K11/ K48-linked conjugates, as several substrates or regulators of the APC/C were enriched in K11/K48-bispecific affinity purifications compared to control K11/gD and K48/gD immunoprecipitations ( Figure S3F ). Candidate substrates included the APC/C co-activator CDC20 that was ubiquitylated at Lys490 ( Figure 2C ). Modification of CDC20 at this site was implicated in spindle checkpoint silencing, a reaction that in vitro is brought about by the APC/C, UBE2S, and branched ubiquitin chains (Alfieri et al., 2016; Meyer and Rape, 2014; Reddy et al., 2007; Williamson et al., 2009; Yamaguchi et al., 2016) .
We confirmed modification of endogenous CDC20 and cyclin A by denaturing purification of K11/K48-branched chains from mitotic cells ( Figure 2C ). Using native affinity purification, we also showed that endogenous NEK2A was decorated with such conjugates ( Figure 2D ). We detected increased K11/K48-specific modification of APC/C substrates if the proteasome was inhibited ( Figures 2C and 2D) , which is consistent with the proposed role of K11/K48-branched chains in protein degradation (Meyer and Rape, 2014) . Together, these results validate the K11/K48-bispecific antibody in vivo and show, to our knowledge for the first time, that endogenous proteins are modified with heterotypic ubiquitin chains. During mitosis, K11/K48-linked conjugates contain multiple blocks of K11-linked chains (Meyer and Rape, 2014) , are assembled by the APC/C, and likely function as proteasome-targeting signals.
K11/K48-Linked Chains Label Newly Synthesized and Aggregation-Prone Proteins
The discovery of K11/K48-branched chains relied on biochemical analyses of the APC/C (Meyer and Rape, 2014) , an approach that cannot be used to reveal roles of heterotypic polymers that are assembled by unknown E3 ligases or act in uncharacterized signaling pathways. As an alternative strategy, we used our bispecific antibody to screen for conditions that show high levels of K11/K48-linked conjugates and hence might depend on their signaling function. We found that K11/K48-linked chains accumulated in cells experiencing proteotoxic stress caused by inhibition of the proteasome, HSP70, or HSP90 ( Figure 3A) . Several other conditions that elicit strong ubiquitylation responses, such as DNA damage, mitochondrial dysfunction, ER overload, or oxidative stress, did not cause a global increase in the abundance of K11/K48-linked chains. Affinity purification of K11/ K48-linked polymers showed a marked enrichment of K11 and high-MW K48 linkages, but not M1 or K63 linkages ( Figure S4A ). Together, these results suggested that proteotoxic stress promotes formation of high-MW heterotypic K11/K48-linked chains, which contribute significantly to the cellular ubiquitin pool.
To dissect the topology of the ubiquitin chains formed under proteotoxic stress, we purified K11/K48-linked conjugates from cells expressing tobacco etch virus (TEV)-cleavable ubiquitin. As described before (Liu et al., 2017; Meyer and Rape, 2014) , treatment of conjugates containing ubiquitin-TEV with TEV protease results in an 2-kDa ''stamp'' per subunit attached to wild-type ubiquitin molecules. Branched chains are characterized by ubiquitin subunits that are modified on two or more lysine residues and, thus, display two or more stamps, whereas mixed chains or independent homotypic polymers produce only a single stamp. We found that cells efficiently synthesize K11/K48-branched chains upon proteotoxic stress (Figures 3B and S4B) . As expected from its mechanism of coincidence detection, the K11/K48-bispecific antibody enriched branched ubiquitin chains more efficiently than a pan-ubiquitin antibody used for comparison ( Figure S4B ).
To characterize the formation of K11/K48-branched chains in cells, we made use of the observation that HSP70 or HSP90 inhibition leads to accumulation of misfolded, aggregation-prone proteins (Bennett et al., 2007; Ellis and Minton, 2006; Hipp et al., 2014) . As aggregates are still recognized by the ubiquitylation, but not the degradation machinery, they can be investigated for ubiquitin marks attached to misfolded proteins in vivo. In agreement with our experiments in lysates, HSP70 and HSP90 inhibition triggered the formation of cytoplasmic aggregates that were extensively decorated with K11/K48-linked chains ( Figures 3C and S4C ). We detected similar K11/K48-positive aggregates in 293T cells, untransformed human embryonic stem cells (hESCs), neuronal precursors, and differentiated neurons ( Figures S4C and S4D ). These findings indicated that multiple cell types respond to the accumulation of aggregationprone proteins with the production of K11/K48-branched chains.
A large fraction of HSP70 and HSP90 clients are newly synthesized proteins that fail to fold upon release from ribosomes (Balchin et al., 2016; Brandman and Hegde, 2016; Harper and Bennett, 2016) . Proteins that have not reached their native conformation even after multiple attempts of chaperone-assisted folding are rapidly degraded by the ubiquitin-proteasome system (Wang et al., 2013 (Wang et al., , 2015a . Suggesting that K11/K48-specific quality control primarily targets such nascent polypeptides, inhibition of mRNA translation by cycloheximide, emetine, or harringtonine prevented the accumulation of K11/K48-linked conjugates , and no K11/K48-positive aggregates were detected under these conditions ( Figures 3C,  S4C , and S4D). By contrast, inhibition of transcription by a-amanitine had no effect ( Figures 3C and 3D) , and cycloheximide treatment did not ablate formation of K11/K48-linked chains during mitosis, when such conjugates label cell-cycle regulators targeted by the APC/C ( Figure S4I ). To directly test for modification of newly synthesized proteins, we treated cells with puromycin, which is incorporated into nascent chains and releases misfolded proteins from ribosomes. Both denaturing and native affinity purification of specific chain types revealed that puromycylated proteins were strongly labeled with K11/K48-linked conjugates (Figures 3E and S4J) , and puromycylated polypeptides were recruited to aggregates that were positive for K11/ K48-linked chains ( Figure 3F ). From these collective results, we infer that cells modify newly synthesized and misfolded proteins with K11/K48-linked ubiquitin chains. TEV/FLAG were grown in the presence of MG132 as indicated. K11/K48-linked chains were affinity-purified using the K11/K48-bispecific antibody and subjected to TEV cleavage. As each attached ubiquitin TEV/FLAG leaves an 2-kDa ''stamp,'' branched ubiquitin molecules with two or more stamps can be detected by aFLAG western blotting (Meyer and Rape, 2014) . Only the relevant MW region of the aFLAG western blot is shown. (C) Aggregating newly synthesized proteins are strongly labeled with K11/K48-linked chains. Cells were treated with either DMSO or the HSP70 inhibitor pifithrin m and then stained for K11/K48-linked chains by using fluorescently labeled K11/K48-bispecific antibodies (yellow). DNA was stained with Hoechst (blue). Inhibition of mRNA translation (cycloheximide, emetine, harringtonine), but not inhibition of transcription (a-amanitine), prevented formation of K11/K48-positive aggregates.
(D) Production of K11/K48-linked chains in cells experiencing proteotoxic stress relies on new protein synthesis. 293T cells were treated with the HSP70 inhibitor pifithrin m, and various inhibitors of mRNA translation or transcription, as described above. K11/K48-linked chains were detected by western blotting using bispecific antibodies. (E) Nascent, misfolded proteins are decorated with K11/K48-linked chains. Ubiquitin conjugates from puromycin-treated 293T cells were purified under denaturing conditions using the indicated antibodies, and modified puromycylated proteins were detected with an antibody against puromycin. (F) Puromycylated proteins accumulate in K11/K48-positive aggregates. HeLa cells were treated with puromycin for 2 hr and analyzed by immunofluorescence microscopy against puromycin (green), K11/K48-linked chains (red), and DNA (blue). The right panel depicts a merged image of the same experiment performed in the presence of cycloheximide. See also Figure S3 .
Identification of Enzymes and Effectors of K11/K48-Specific Quality Control
Previous work had indicated that quality-control networks direct up to 15% of newly synthesized proteins toward ubiquitin-and proteasome-dependent degradation (Wang et al., 2013 ), yet the E3 ligases or ubiquitin-binding proteins of this pathway have not been identified. Our discovery that nascent proteins are modified with K11/K48-branched chains offered an opportunity to discover components of this quality-control network: we hypothesized that effectors, such as chaperones or proteasome shuttles, bind the ubiquitylated targets, while E3 ligases might modify themselves with the same K11/K48-linked conjugates that they transfer onto substrates. We therefore used label-free quantitative mass spectrometry to isolate proteins that were enriched in K11/K48 compared to K11/gD and K48/gD control immunoprecipitations. To focus on quality control rather than cell division, we conducted these experiments in puromycin-treated, asynchronous cells with little or no APC/C activity. We found that HSP90 as well as the ribosome-associated chaperone BAG6 were enriched in K11/K48-specific affinity purifications ( Figure 4A ). HSP70 was also abundant in these precipitations, yet, due to high background 
. Identification of Enzymes and Effectors of K11/K48-Specific Quality Control
(A) Ubiquitin chains were purified from puromycin-treated cells using K11/K48-bispecific, K11/gD, or K48/gD control antibodies. 5 biological and 1 technical replicates were used for label-free quantitative mass spectrometry to identify proteins enriched in K11/K48-bispecific purifications (colored proteins were significantly enriched compared to control purifications; p < 0.01). Axis show enrichment compared to K11 (TSC K11/K48 -TSC K11 ) or K48 linkages (TSC K11/K48 -TSC K48 ), based on average TSC/experiment. (B) Ubiquitin chains of the indicated topology were affinity-purified from 293T cells treated with pifithrin m and analyzed for co-purifying proteins using western blotting and specific antibodies. Cycloheximide was added as noted to prevent the production of newly synthesized proteins. (C) p97, BAG6, and p62/SQSTM1 bind K11/K48-linked chains in an mRNA-translation-dependent manner. Endogenous p97, BAG6, or p62 were affinity-purified from cells treated with the HSP70 inhibitor pifithrin m. When indicated, cells were also exposed to cycloheximide. Bound K11/K48-linked ubiquitin chains were detected by western blotting using the K11/K48-bispecific antibody. (D) Enzymes and effectors of K11/K48-specific quality control co-localize with K11/K48-positive protein aggregates. HeLa cells treated with either proteasome or HSP70 inhibitors were stained for K11/K48-linked chains (red); binding proteins identified by mass spectrometry (green), and DNA (blue). See also Figures S4 and S5.
Figure 5. Functional Analysis of Components of K11/K48-Specific Quality Control
(A) UBR4 and UBR5 assemble most K11/K48-linked chains during quality control. 293T cells were co-depleted of UBR4 and UBR5, treated with MG132, and analyzed for ubiquitin chains of different topologies using western blotting. (B) UBR4 and UBR5 target puromycylated proteins for degradation. 293T cells were co-depleted of UBR4 and UBR5 and treated with puromycin, and the stability of puromycylated proteins was determined by cycloheximide chase and western blotting. (C) UBR4 and UBR5 complexes synthesize K11/K48-linked chains in vitro. Endogenous FLAG UBR4 and FLAG UBR5 were affinity-purified from CRISPR/Cas9-edited 293T cells, incubated with E1, the E2 UBE2D3, and ATP (as indicated). Reactions were supplemented with wild-type (WT) ubiquitin; a mixture of ubiquitin K11R . Conjugates were treated with TEV-protease as indicated and analyzed by aFLAG immunoblotting. The presence of two or more FLAG-positive stamps indicates branching. As control, ubiquitylation reactions were performed with UBE2G2/gp78, which only assemble homotypic K48-linked chains. (E) UBR5 produces branched ubiquitin trimers. UBR5 and the K11-specific UBE2S were incubated with ubiquitin DGG (a mutant that can be modified, but not used as a modifier) and methyl-ubiquitin (which can be transferred to ubiquitin DGG , but not further modified), as indicated. Formation of K11-or K48-positive ubiquitin conjugates was analyzed by linkage-specific western blotting. The presence of both UBE2S and UBR5 leads to formation of branched ubiquitin trimers.
binding, it was not enriched compared to the control reactions. In addition, we noted strong enrichment of the E3s UBR4, UBR5, and HUWE1 ( Figure 4A ), while we found no binding for the APC/C, which is mainly active during mitosis, Listerin or ZNF598, which modify proteins on stalled ribosomes (Bengtson and Joazeiro, 2010; Brandman et al., 2012; Juszkiewicz and Hegde, 2017; Shao et al., 2015; Sundaramoorthy et al., 2017) , or CHIP, which can ubiquitylate HSP70 or HSP90 clients (Meacham et al., 2001; Younger et al., 2006) . As effectors of K11/ K48-linked chains, we identified the p97/VCP segregase and its receptors, including NSFL1/p47; proteasome shuttles, such those of the UBQLN family; low amounts of p62/SQSTM1, which had been implicated in proteasomal and autophagosomal delivery; and the 26S proteasome ( Figure 4A ). By contrast, we did not recover any E3 ligase, deubiquitylase, or effector with M1-or K63-linkage specificity, which underscores the specificity of our antibody and approach.
We validated these results by affinity purification coupled to western blotting, which confirmed the strong interaction of K11/K48-linked chains with endogenous p97, BAG6, UBQLN2, p62, UBR5, and HUWE1 ( Figure 4B ). BAG6, p62, and UQBLN2 bound K11/K48-linked chains only if new proteins were synthesized, while the E3s UBR5 and HUWE1 were enriched in the presence of cycloheximide. The latter behavior is expected if the purification of E3 ligases was due to automodification with K11/K48-linked chains. Reciprocal affinity purification of proteasome and p97/VCP receptors, or endogenous BAG6, p62, or p97/VCP, confirmed that these proteins efficiently precipitated K11/K48-linked chains ( Figures 4C, S5A , and S5B), and, as seen upon expression of ubiquitin-TEV, proteasome and p97/ VCP adaptors interacted efficiently with branched ubiquitin chains ( Figure S5C ). BAG6, UBR5, p97/VCP, p62, and HSP90 also accumulated at K11/K48-positive aggregates ( Figures 4D,  S5D , and S5E), while co-localization was neither seen with a marker of stress granule formation ( Figure S5F ), nor with unrelated ubiquitin-binding proteins not identified in our proteomic experiments ( Figure S5G ). Providing further validation, depletion of the BAG6 chaperone increased the abundance of puromycylated proteins and extended the time needed for their clearance ( Figure S5H ).
Among the candidate components of this quality-control network, we were intrigued by the small number of E3 ligases that were enriched in K11/K48-specific affinity purifications (Figure 4A ). This observation raised the possibility that we could identify the major enzymes responsible for K11/K48-branched chain production during proteotoxic stress. Indeed, by depleting combinations of candidate E3s we found that loss of both UBR4 and UBR5, using multiple small interfering RNA (siRNA) sequences to ensure on-target specificity, was sufficient to inhibit the formation of most K11/K48-linked chains in cells with proteotoxic stress ( Figures 5A and S6A ). The same treatment strongly stabilized puromycylated proteins ( Figure 5B ). By contrast, depletion of Listerin or the APC/C-E2 UBE2S, which were not enriched in our proteomic studies, did not affect production of K11/K48-branched chains and did not prolong the half-life of puromycylated proteins (Figures S6B-S6D ). As UBE2S was required for K11/K48-linked chain formation during mitosis ( Figure 2B ), these results highlight that different enzymes produce K11/K48-linked chains during mitosis and upon proteotoxic stress, respectively.
To ascertain whether UBR4 and UBR5 synthesize K11/K48-linked chains, as suggested by these genetic analyses, we used CRISPR/Cas9 genome editing to integrate a FLAG epitope into the UBR4 and UBR5 loci. This allowed us to purify endogenous complexes containing these E3 ligases and interrogate them for their ubiquitylation activity and specificity. Importantly, both UBR4 and UBR5 complexes synthesized K11/K48-linked chains in vitro, with the HECT-E3 UBR5 being the more efficient enzyme ( Figure 5C ). Incubation with mixtures of ubiquitin K11R and ubiquitin K48R suggested that UBR5 produced branched ubiquitin chains, as seen in cells ( Figure 3B ), while UBR4 appeared to synthesize mixed chains containing multiple linkages ( Figures 5C and S6E) . We confirmed the very efficient formation of branched ubiquitin conjugates by UBR5 using the ubiquitin-TEV assay ( Figure 5D ) and directly showed that UBR5 cooperated with a K11-specific enzyme to produce K11/K48-branched trimers ( Figure 5E ). By using single-Lys ubiquitin mutants, we noted that endogenous UBR5 displayed a striking preference for Lys48 of ubiquitin ( Figure 5F ), suggesting that it produces branched conjugates that contain multiple blocks of K48-linked chains.
Having reconstituted K11/K48-branched chain formation allowed us to analyze detection of these conjugates by ubiquitin effectors. Thus, we used UBR5 to generate either K11/K48-branched or homotypic K48-linked polymers, and incubated these conjugates with immobilized proteasomal or p97/VCP substrate adaptors. Similar to mitotic K11/K48-branched chains (Meyer and Rape, 2014), we found that the proteasomal substrate adaptor HHR23A and the p97/VCP adaptor NSFL1/p47, both identified as effectors in our proteomic analysis, bound K11/K48-branched chains with much higher affinity than homotypic K48-linked chains (Figures 5G and S6F) . Consistent with these results, proteasome inhibition strongly stabilized both puromycylated proteins and K11/K48-linked chains in cells (Figure 5H) . Thus, UBR4 and UBR5 are key quality-control E3 ligases that decorate targets with K11/K48-branched chains to allow for efficient substrate recognition by the segregase p97/VCP and the 26S proteasome. (F) UBR5 strongly prefers K48 linkages. Endogenous UBR5 complexes were incubated with indicated single-Lys ubiquitin mutants and analyzed by aUbiquitin immunoblotting. (G) K11/K48-branched ubiquitin chains produced by UBR5 show strongly increased affinity to the p97/VCP adaptor NSFL1/p47 than homotypic K48-linked chains. K11/K48-branched or K48-linked chains were assembled by UBR5 using wild-type-ubiquitin or ubiquitin K48 and incubated with immobilized p97-NSFL1
complexes. Binding reactions were stopped at the indicated times and analyzed by aUbiquitin immunoblotting.
(H) The proteasome targets puromycylated and K11/K48-labeled proteins for degradation. The stability of puromycylated proteins was analyzed in cells treated with DMSO or MG132, and puromycylated proteins or K11/K48-linked chains were detected by western blotting using specific antibodies. See also Figure S6 .
K11/K48-Specific Quality Control Is Linked to Neurodegenerative Diseases
Recent CRISPR/Cas9 screens had identified components of K11/K48-specific quality control, including the E3s UBR4 and UBR5, as essential proteins in human cells (Wang et al., 2015b) , and deletion of UBR4 or UBR5 in mice resulted in early lethality (Saunders et al., 2004; Tasaki et al., 2013) . In addition, mutations in enzymes or effectors of this quality-control network had been linked to neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), or ataxia ( Figure S7A ). This implied that K11/K48-specific quality control is an essential pathway that might prevent the accumulation of neurotoxic proteins. To test this notion, we focused on HD, which is caused by CAG-repeat expansions in HTT that produce a Huntingtin (HTT) protein with more than 35 glutamine residues in its N-terminal domain. UBR5 was recently identified as a candidate genetic modifier for the age of onset of HD (Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium, 2015). Repeat-associated non-ATG translation of HTT yields peptides that resemble BAG6 substrates (Bañ ez-Coronel et al., 2015) , and HTT aggregation increases levels of K11 and K48 linkages attached to unknown substrates (Bennett et al., 2007) .
Most importantly, an investigation of K11/K48-ubiquitylated proteins revealed modification of endogenous HTT at Lys337 in four independent experiments. Consistent with these observations, aggregates of pathological 73Q-HTT were strongly decorated with K11/K48-linked chains in cancer cells, embryonic stem cells, or differentiated neurons ( Figures 6A-6C ). The expression of 73Q-HTT, but not benign 23Q-HTT, also induced an overall increase in K11/K48-linked chains in these cells ( Figure S7B ). Similar observations were made without overexpression in brains of an HD mouse model (Langfelder et al., 2016) , where 175Q-HTT aggregates were labeled with K11/K48-linked conjugates ( Figure 6D) . Thus, the K11/K48-bispecific antibody detects its epitope not only in biochemical experiments or cell culture, but also in tissues. Denaturing purification of HTT as well as native precipitation of ubiquitin chains strongly suggested that 73Q-HTT, but less so 23Q-HTT, was modified with K11/K48-linked chains (Figures 6E and S7C) , which was reduced by co-depletion of UBR4 and UBR5 ( Figure S7D ). By combining denaturing purification of HTT with expression of ubiquitin-TEV, we found that 73Q-HTT, but not 23Q-HTT, was modified with branched chains ( Figure 6F ). In line with these results, 73Q-HTT bound BAG6 (Figure S7E ), See also Figure S7. and BAG6, UBQLN2, p62, and p97 were efficiently recruited to K11/K48-positive aggregates of 73Q-HTT ( Figure 6G ). In contrast to 73Q-HTT, ALS-causing FUS variants were not labeled with K11/K48-linked chains under these conditions (Figure S7F) . We conclude that pathological HTT variants, but not all aggregation-prone proteins, are processed by K11/K48-specific quality control. These results raised an intriguing possibility for how aggregation-prone proteins could accelerate the progression of neurodegenerative disorders: if the load capacity of K11/K48-specific quality were limited, expression of pathological HTT might negatively impact processing of newly synthesized proteins, and vice versa. To test this possibility, we expressed 73Q-HTT to form K11/K48-positive aggregates in hESCs or neurons. We then inhibited the proteasome or HSP70 to stabilize misfolded nascent polypeptides and asked whether accumulation of the latter quality-control substrates affected the ubiquitylation or processing of 73Q-HTT. Strikingly, proteasome or HSP70 inhibition caused the redistribution of K11/K48-linked chains from 73Q-HTT to distinct aggregates, which was dependent on ongoing protein synthesis ( Figures 7A, 7B , and S7G). Other components of K11/K48-specific quality control followed the ubiquitin signal: while BAG6 and UBQLN2 marked 73Q-HTT aggregates in control cells, colocalization was lost upon HSP70 or proteasome inhibition, and production of new proteins was required for this effect (Figure 7C) . The redirection of K11/K48-linked chains toward nascent proteins diminished the ability of cells to counteract aggregation: depletion of BAG6 not only delayed clearance of puromycylated proteins ( Figure S5H ) but also increased the number of 73Q-HTT foci ( Figure 7D ). Thus, 73Q-HTT and newly synthesized proteins compete for a limited pool of enzymes or effectors of the essential K11/K48-specific quality-control machinery.
DISCUSSION
The recent biochemical discovery of heterotypic ubiquitin chains and their potential roles in mitosis and inflammatory signaling raised the possibility that cells use combinations of multiple ubiquitin linkages to encode biological information. However, in the absence of any method to follow physiological mixed or branched chains, i.e., without in vitro reconstitution, purification of ubiquitin chains from lysates, or expression of engineered ubiquitin variants, the abundance and physiological relevance of complex ubiquitin chain types remained poorly understood. To address this gap in our understanding of ubiquitin-dependent signaling, we established bispecific antibodies that detect endogenous K11/K48-linked chains in cells. As demonstrated here, such antibodies allow for identification of signaling events regulated by heterotypic chains; discovery of ubiquitylation substrates, enzymes, and effectors; and diagnostic monitoring of aberrant ubiquitin signaling associated with human pathologies. Bispecific antibodies therefore provide a means to dissecting the increasing complexity of ubiquitin-dependent signaling.
Substrates of K11/K48-Branched Ubiquitin Chains
Having a tool in hand to follow the formation of K11/K48-linked chains, we found that heterotypic conjugates target mitotic regulators and misfolded nascent polypeptides for degradation.
These findings place K11/K48-linked chains at the heart of cell-cycle and protein quality control, two conditions that rely on high proteasome activity: while the APC/C ensures that a large number of substrates are turned over during the short time span of mitosis (Sivakumar and Gorbsky, 2015), translation-coupled quality control triages up to 15% of newly synthesized proteins (Balchin et al., 2016; Harper and Bennett, 2016; Wang et al., 2013 Wang et al., , 2015a . Even though the architecture of K11/K48-branched chains differs during mitosis and quality control ( Figure 7E ), physiological and biochemical evidence suggests that both types of K11/K48-branched chains afford a higher affinity toward the proteasome and its associated segregase p97/VCP than homotypic K11-or K48-linked conjugates (Meyer and Rape, 2014). While we do not wish to exclude mechanisms of branch recognition, we speculate that the higher affinity of p97/VCP and proteasomal receptors toward K11/K48-branched chains is due to a branching-dependent increase in the local concentration of proteolytic ubiquitin chains. We propose that K11/K48-branched chains are proteasomal priority signals that allow cells to rapidly clear specific proteins.
As we have started to dissect the mechanism of substrate recognition during K11/K48-specific quality control, it is interesting to note that chaperones bind misfolded proteins through extended hydrophobic stretches (Balchin et al., 2016; Hartl et al., 2011) . Structural studies showed that the APC/C also recognizes its mitotic targets through extended low complexity motifs referred to as D-or KEN-boxes (Brown et al., 2016; Chang et al., 2015) . In addition, mitotic regulators are often incorporated into stable complexes (Huttlin et al., 2015) , and misfolded proteins rapidly engage in oligomeric interactions en route to aggregation (Bemporad and Chiti, 2012) . These parallels might explain a striking overlap between the enzymes of cell-cycle and protein quality control: while the APC/C was identified as an E3 ligase that prevents protein aggregation in C. elegans (Brehme et al., 2014) , the quality-control E3 UBR5 vice versa binds the APC/C and regulates the spindle checkpoint (Scialpi et al., 2015) . Moreover, p97/VCP, an effector of K11/K48-specific quality control, was originally identified as a cell division cycle mutant (Moir et al., 1982) . It therefore appears that different pathways converged on ubiquitin chain branching as a common solution to the need for efficient turnover of difficult or abundant proteasome substrates ( Figure 7E ).
Enzymes of K11/K48-Linked Ubiquitin Chain Formation
Consistent with in vitro studies (Meyer and Rape, 2014), we identified the APC/C as the major E3 ligase for the production of K11/ K48-branched chains during mitosis ( Figure 7E ). The ability of the APC/C to synthesize such conjugates depends on UBE2S, an E2 enzyme that branches blocks of 6-7 K11-linked subunits off chains initiated by UBE2C or UBE2D (Meyer and Rape, 2014; Wickliffe et al., 2011) . Two different E3 ligases, UBR4 and UBR5, carry the main load of K11/K48-linked chain synthesis during proteotoxic stress ( Figure 7E ). Co-depletion of UBR4 and UBR5 eliminated most K11/K48-linked chains during quality control and strongly inhibited the proteasomal degradation of puromycylated proteins. Reconstitution assays revealed that UBR4 and UBR5 complexes efficiently synthesize K11/K48-linked chains, with UBR5 likely branching multiple K48-linked It is interesting to note that UBR4 and UBR5 are distinct from ubiquitylation enzymes that had previously been implicated in proteostasis, including Listerin, which targets nascent polypeptides on stalled ribosomes (Bengtson and Joazeiro, 2010; Brandman et al., 2012; Shao et al., 2015) ; CHIP, which ubiquitylates clients of the HSP70 and HSP90 chaperones (Meacham et al., 2001; Scaglione et al., 2011) ; HUWE1, which helps degrade proteins that fail to engage an obligate binding partner (Sung et al., 2016; Xu et al., 2016) ; or the yeast UBR1 and SAN1, which modify unfolded proteins in the cytoplasm and nucleus, respectively (Gardner et al., 2005; Shemorry et al., 2013) . This suggests that the quality-control machinery discovered here complements known pathways that ensure proteostasis in human cells. The enzymes and effectors of K11/K48-specific quality control appear to be well suited to safeguard new protein synthesis: UBR5 contains an RNA-binding domain that might direct it to translating polysomes, while effectors of this pathway, such as BAG6, p97, and the proteasome, frequently operate in association with the ribosome (Brandman et al., 2012; Hessa et al., 2011; Rodrigo-Brenni et al., 2014; Sha et al., 2009; Turner and Varshavsky, 2000; Verma et al., 2013) . These observations imply that K11/K48-specific quality control immediately checks the integrity of newly synthesized proteins to prevent their deleterious aggregation.
K11/K48-Linked Chains and Neurodegeneration
In addition to newly synthesized proteins, K11/K48-branched chains also decorate pathological variants of HTT, and enzymes and effectors of K11/K48-linked conjugates are mutated in neurodegenerative diseases, including HD (Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium, 2015; Weishaupt et al., 2016) . As the proteasome is unable to clear aggregates, we expect soluble oligomeric HTT to be the major target of K11/K48-specific quality control; the neurotoxicity of this oligomeric HTT species (Miller et al., 2011) might explain why this substrate is modified with a proteasomal priority signal that ensures its rapid clearance from cells. As the load capacity of the K11/K48-specific network to handle both nascent polypeptides and pathological HTT is limited, neurotoxic proteins could exert their effects by allowing the accumulation of newly synthesized, misfolded proteins that in turn impede multiple cellular pathways. Consistent with this idea, inhibition of protein synthesis, a condition that reduces the burden for K11/K48-specific quality control, ameliorated phenotypes of protein aggregation (Das et al., 2015) , while expression of mutant HTT, a condition that exacerbates the need for the K11/K48-specific pathway, caused misfolding of other metastable proteins in C. elegans (Gidalevitz et al., 2006) . Although more work is required to investigate the crosstalk between substrates, our results raise the possibility that activators of K11/K48-specific quality control could provide therapeutic benefit against neurodegenerative disorders.
In summary, by developing a method to detect and purify K11/ K48-linked chains, we revealed roles for endogenous heterotypic ubiquitin polymers in cell-cycle and protein quality control. Ubiquitin contains eight sites for polymer formation, and cells could assemble 28 distinct chain types with two linkages and a large number of more complex conjugates. Even if few combinations exert specific functions, ubiquitin-dependent signaling is likely to be more complex than anticipated, yet our work describes a powerful strategy to decipher this essential system for cellular information transfer.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mammalian cell culture and stable cell lines Human embryonic kidney (HEK) 293T cells and HeLa cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS. Cells were routinely screened for mycoplasma contamination. Plasmids transfections were either with calcium phosphate precipitation method or with polyethylenimine (PEI). Lentiviruses were produced in 293T cells by cotransfection of lentiviral constructs with packaging plasmids (Addgene) forand was harvested 48 and 72 hr post-transfection. Stable cell lines were maintained in DMEM media supplemented with 10% Tet-FBS. To induce expression of stably transfuced Htt-GFP constructs, media was supplemented with 1mg/ml Doxycylcine.
Human embryonic stem cell culture and differentiation Human embryonic stem (hES) H1 cells (WA01) were maintained under feeder free conditions on Matrigel-coated plates (#354277, BD Biosiences) in mTeSRTM1, (#05871/05852, StemCell Technologies Inc.) with daily medium change. They were routinely passaged with collagenase (#07909, StemCell Technologies Inc.) and ReLesR (#05872, StemCell Technologies Inc.). For transduction, single cell suspensions were prepared by treatment of hES cells with accutase (#07920, StemCell Technologies Inc.) and 0.5 3 106 hES H1 cells per well of a 6-well were centrifuged with lentiviruses in the presence of 6 mg/ml Polybrene (Sigma) and 10 mM Y-27632 ROCK inhibitor (Calbiochem) at 1000 g at 30 C for 90min. After spinfection, media was changed to mTeSRTM1 supplemented with 10 mM Y-27632 ROCK inhibitor (Calbiochem). hES H1 cells were selected with appropriate antibiotic (200 mg/ml G418 for pINDCUER20) for 7 days and used in experiments.
For differentiation into neural progenitor cells, hES H1 cells were subjected to a neural conversion protocol using STEMdiffTM Neural Induction Medium (#05831, StemCell Technologies Inc.) and a monolayer culture method according to the manufacturer's guidelines (#28044, StemCell Technologies Inc.) and as previously described. In brief, single cell suspensions were prepared by treatment of hES cells with accutase (#07920, StemCell Technologies Inc.) and 2.0 3 106 cells were seeded per well of a 6-well plate in STEMdiffTM Neural Induction Medium supplemented with 10 mM Y-27632 ROCK inhibitor. Neural conversion was performed with daily medium change. At day 6 of differentiation cells were split on Matrigel-coated coverslips for fluorescence microscopy analysis at day 9. For differentiation into neurons, hES H1 cells subjected to neural conversion for 6 days as described above, passaged, and maintained in DMEM F12 containing 1x B-27 Supplement (17504044, GIBCO) to promote spontaneous differentiation into neurons ((#28044, StemCell Technologies Inc.) . At day 20 of differentiation cells were split on Matrigel-coated coverslips for fluorescence microscopy analysis at day 25. For hES H1 cells transduced with pINDCUER20 constructs, expression of the transgenes was induced by adding 1ug/mL doxycyclin to the media for 72h before immunoblot or immunofluorescence analysis.
METHOD DETAILS
Bispecific Antibody Cloning Bispecific antibodies were generated using knobs-into-holes heterodimerization technology24. The heavy chain variable domains of the previously described anti-K11 polyubiquitin linkage-specific antibody (clone 2A3/2E6) (Matsumoto et al., 2010) , the anti-K48 polyubiquitin linkage-specific antibody (clone Apu2.07) (Newton et al., 2008) , and a non-specific anti-gD control antibody were subcloned into a modified pRK vector (Genentech) containing the human IgG1 heavy chain constant domains with either the knob (T366W) or hole (T366S, L368A, and Y407V) mutations in the CH3 domain. The light chain variable domains were similarly subcloned into a modified pRK vector (Genentech) containing the human kappa light chain constant domain. The pRK vector carries a constitutive strong signal peptide for extracellular expression in mammalian cells. For this study, the anti-K11 antibody was cloned as both knob and hole mutants, the anti-K48 was cloned as a hole mutant, and the anti-gD was cloned as a knob mutant.
Knob and Hole Half Antibody Expression, Purification, and Annealing The knob and hole half antibodies were expressed separately in CHO cells and isolated individually. Light chain and heavy chain plasmids for a given knob or hole half antibody were transiently co-transfected into CHO cells using PEI as previously described (Wong et al., 2010) . Half antibodies were purified over MabSelect SuRe resin (GE Healthcare), eluted with 50 mM sodium citrate, 150 mM NaCl, pH 3.0, followed by pH adjustment to 5.0 with 10% (v/v) of 200 mM arginine, 137 mM succinate, pH 9.0. Bispecific antibodies were assembled in vitro using a modified version of the previously described method of annealing, reduction, and oxidation (Shatz et al., 2013) . Briefly, the desired knob and hole half antibodies were mixed at a 1:1 mass ratio and the pH of the mixture was adjusted to 8.5 with 15% (v/v) of 800 mM arginine, pH 10.0. A 200-fold molar excess of reduced glutathione (Sigma Aldrich) in 800 mM arginine, pH 10.0 was added and the assembly reaction was incubated at room temperature for 72 hr with exposure to air to allow annealing of the knob and hole half antibodies and formation of the hinge disulfides.
Bispecific Antibody Purification
Assembled bispecific antibodies were purified by hydrophobic interaction chromatography (HIC). Briefly, the assembly reaction was conditioned with 3 volumes of buffer A (25 mM sodium phosphate, 1 M ammonium sulfate, pH 6.5) to a final concentration of 0.75 M ammonium sulfate. The assembly reaction was filtered, loaded onto a 5 mm, 7.8 3 75 mm ProPac HIC-10 column (Dionex), followed by washing with buffer A. A 0%-100% buffer B (25 mM sodium phosphate, pH 6.5, 25% isopropanol) linear gradient over 40 column volumes (CVs) was performed to separate the bispecific antibody from any unreacted half antibodies or aggregated protein. Identity of the eluting peaks was monitored by SDS-PAGE and mass spectrometry (see below for method details).
The bispecific antibodies were further purified by cation-exchange chromatography (CEX). Briefly, the HIC pooled material was dialyzed into 20 mM sodium acetate, pH 5.0, loaded onto a 10 mm Mono S 5/50 GL column (GE Healthcare), and washed with buffer A (20 mM sodium acetate, pH 5.0). A 0%-100% buffer B (20 mM sodium acetate, pH 5.0, 1 M NaCl) linear gradient over 40 CVs was performed and the desired fractions pooled. The purified bispecific antibodies were formulated in 20 mM histidine acetate, 240 mM sucrose, 0.02% Tween-20, pH 5.5.
SEC-MALS
50 mg of antibody was injected onto a 3.5 mm, 7.8 mm x 300 mm XBridge Protein BEH analytical SEC 200 Å column (Waters) at 1 mL/ min using an Agilent 1260 Infinity HPLC with 20 mM histidine acetate, 300 mM NaCl, pH 5.5 as the mobile phase. Proteins eluted from the analytical SEC column were directly injected onto a Wyatt DAWN HELEOS II/Optilab T-rEX multi-angle light scattering detector to measure molar mass and polydispersity.
Mass Spectrometry 30 mg of antibody was deglycosylated with 2 units of PNGaseF (NEB) in the presence or absence of 2 units of carboxypeptidase B (Roche) at 37 C overnight prior to mass spectrometry analysis. 2 mg of antibody was then injected onto a 3 mm, 4.6 3 50 mm reversephase chromatography PLRP-S column (Agilent) at 1 mL/min using an Agilent 1290 Infinity UHPLC. A 0%-100% buffer B gradient over 3 min was performed with 0.05% trifluoroacetic acid (TFA) in water (buffer A) and 0.05% TFA in acetonitrile (buffer B), followed by a 100% buffer B wash for 1 min. Proteins eluted from the reverse-phase column were directly injected onto an Agilent 6230 electrospray ionization time-of-flight mass spectrometer (ESI-TOF) for intact mass measurement.
Fluorescent Labeling of Antibodies
The anti-K11 monospecific antibody and the anti-K11/K48 bispecific antibody were labeled with Alexa Fluor 488 and Alexa Fluor 546, respectively, according to the manufacturer's instructions using Alexa Fluor Protein Labeling Kits (ThermoFisher). Unreacted free dye was removed through extensive dialysis. Six and 8 moles of Alexa Fluor 488 and Alexa Fluor 546, respectively, per mole of antibody was conjugated.
Surface Plasmon Resonance
Affinities of the antibodies were determined by surface plasmon resonance (SPR) using a BIACORE 3000 system (GE Healthcare). Ubiquitin proteins were immobilized on CM5 sensor chips (GE Healthcare) using the amine-coupling method with different surface densities denoted by the difference in resonance units (RUs). The 1:1 diubiquitin mixture was generated by mixing K11-and K48-linked diubiquitin in an equimolar ratio, followed by immobilization on the sensor chip. All analytes were tested in the IgG format to demonstrate avidity. Analytes were run at the indicated concentrations in HBS-P buffer (0.01 M HEPES, 0.15 M NaCl, and 0.005% v/v surfactant P20, pH 7.4). For the K11/K48 bispecific, K11 monospecific, and K48 monospecific antibodies, concentrations of 10 nM, 5 nM, 2.5 nM, 1 nM and 0 nM (buffer alone) were run in duplicate. For the K11/gD and K48/gD bispecific control antibodies concentrations of 50 nM, 30 nM, 10 nM, 5 nM, 1 nM, and 0 nM (buffer alone) were run in duplicate. Following a dissociation period of 600 s, the chip surface was regenerated with 40 mM HCl. All Biacore sensorgrams were analyzed with the Biaevaluation 4.1 software (GE Healthcare). All experimental refractive index measurements were normalized by subtraction of the reference flow cell responses. Representative measurements from three independent experiments of the kinetic constants and binding constants are shown.
In vitro transcription/translation 35 S-labeled cyclin A was synthesized by incubating pCS2-cyclin A plasmids in rabbit reticulocyte lysates (RRL) in the presence of 35 S-Met for 2 hr at 30 C. 35 S-labeled cyclin A was used as a substrate for the APC/C in in vitro ubiquitylation assays as described. The reaction was terminated via the addition of urea buffer (8M urea, 2% Triton X-100, 20mM Tris pH 7.5, 135mM NaCl, 1mM EDTA, 1.5mM MgCl2, and 10% glycerol supplemented with 10mM N-Ethylamine and protease inhibitors (Roche)) and was then supplemented with an equal volume of lysis buffer without urea or Triton X-100. Immunoprecipitations were performed as described above using the indicated antibodies and analyzed via SDS-page and autoradiography. Signals were quantified using ImageJ software.
Immunofluorescence microscopy For immunofluorescence analysis, HeLa cells were seeded on coverslips and fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.3% Triton X-100 for 30 min. Cells were blocked with 2% BSA, 0.1% Triton X-100. hES H1 cells were seeded on Matrigel-coated coverslips using accutase, fixed with 3.7% formaldehyde for 10 min, permeabilized with 0.3% Triton for 20 min. After fixation and permeabilization, cells were stained with indicated antibodies or Hoechst. Images were taken using Zeiss LSM 710 confocal microscope and processed using ImageJ.
For quantification of K11/K48 positive aggregates, HeLa cells were treated with MG132 or MG132 and cycloheximide for different time spans and were imaged using the 60x objective of the Zeiss LSM 710 confocal microscope. The number of cells containing K11/ K48 positive aggregates was counted; the number of aggregates and their size were determined using the count particle function in ImageJ. To analyze the number of 73Q-HTTGFP inclusion bodies and the number of 73Q-HTTGFP inclusion bodies modified with K11/48 heterotypic chains, 73Q-HTTGFP-expressing hES H1 cells were subjected to indicated drug or siRNA treatments, stained them with K11/48-bispecific antibodies, and analyzed them by indirect immunofluorescence microscopy. Images were taken for each condition using a Zeiss LSM 710 confocal microscope with a 20x objective followed by quantification of the average number of 73Q-HTT inclusion bodies per frame (green channel) and average number of K11/48-positive 73Q-HTT inclusion bodies per frame (red channel) using the count particle function in ImageJ. The average number of K11/48-positive 73Q-HTT inclusion bodies per frame was normalized to the average number of 73Q-HTT inclusion bodies per frame. Error bars represent standard deviation of the mean of at least three biological replicates (> 10 frames each containing > 200 cells were counted per replicate).
Immunohistochemistry
For double-staining of mHtt aggregates and K11/K48-linked chains in mouse brain samples, 40mm coronal sections of 6-month Q175 HD Knock-in mice or wild-type mice were washed in PBS and blocked with 3% bovine serum albumin and 2% normal goat serum (Vector Labs) in PBS with 0.2% Triton X-100 at room temperature for 1 hr. Sections were then incubated with anti-huntingtin protein antibody (clone mEM48, 1:150; Millipore MAB5374) and K11/K48 antibody (1:500) in blocking buffer overnight at 4 degree. After three 10 min washes in PBS with 0.1% Triton X-100, the sections were incubated with biotinylated goat anti-mouse antibody (1:300) (Vector Labs) for 2h at room temperature. Following another three 10 min washes, the sections were incubated for 2h with anti-human-488 (1:300) and Streptavidin, Alexa Fluor 594 conjugate (1:300, Thermo Fisher Scientific) in blocking buffer. The sections were washed again and mounted with antifade mounting medium with DAPI (Vector Labs).
Cellular stress assays
To identify conditions of K11/K48-linked chain formation HEK293T or HeLa cells were treated with different drugs: Epoxomycin (1mM, 6h, Sigma-Aldrich), MG132 (10mM, 6h, Sigma-Aldrich), Pifithrin m (10mM, 6h, Sigma-Aldrich), VER155008 (40mM, 6h, Sigma-Aldrich), 17 DMAG (1mM, 6h, Sigma-Aldrich), Chloroquine (100mM, 6h, Abcam), DBEQ (10mM, 6h, Sigma-Aldrich), Oligomycin/Antimycin (each 10mM, 1h, Sigma-Aldrich), CCCP (10mM, 2h, Abcam), Cycloheximide (100mg/mL, 6h, Sigma-Aldrich), Puromycin (25mM, 1h, SigmaAldrich), DTT (2mM, 6h), Tunicamycin (10mg/mL, 2h, Sigma-Aldrich), Doxorubicin (5mM, 6h, Sigma-Aldrich). Translation and transcription inhibitors were used at the following concentrations: Cycloheximide (100mg/ml), Harringtonine (2mg/ml), Emetine (20mg/ ml), Puromycin (1mg/ml), a-Amanitin (5mg/ml). Accumulation of K11/K48-linked chains was monitored by western blot or immunofluorescence microscopy.
Cell synchronization
HeLa cells were first synchronized in S-phase with 2 mM thymidine for 24h. Cells were then washed with PBS and released into fresh DMEM/10% FBS media for 3h. Finally, cells were treated with 10ng/ml nocodazole or 5mM STLC for 11h and arrested in prometaphase. For progression through mitosis, cells were harvested via pipetting, washed with PBS, and released into fresh media. Samples were taken at indicated time points and analyzed via western blot. For proteasome inhibition, cells were released from prometaphase for 90min to silence the spindle checkpoint before treatment with 20mM MG132. For Ube2S depletion, cells were first transfected with 10nM Ube2S or control siRNA as described above, 24h prior to synchronization. Figure S1 . K11/K48-Bispecific Antibody Characterization, Related to Figure 1 (A) Outline of bispecific antibody purification. Knob and hole half antibodies were separately expressed in CHO cells and affinity purified individually. Bispecific antibodies were assembled from half antibodies in vitro using annealing, reduction, and oxidation. (B) SDS-PAGE analysis of knob and hole half antibodies and assembled bispecific antibodies following purification. Samples were run in the absence or presence of DTT. The HL label denotes a half antibody species and the H 2 L 2 label denotes a full antibody. In the reduced samples the heavy chains (H) and light chains (L) are indicated. (C) Analytical size-exclusion analysis of the anti-K11 knob and anti-K48 hole half antibodies and the assembled anti-K11/K48 bispecific antibody. Monomer, homodimer, and heterodimer peaks are indicated and molecular weights were verified by light scattering (see Table S1 ). (D) Mass spectrometry analysis of the purified anti-K11/K48 bispecific antibody. Top panel: without carboxypeptidase B (CPB); bottom panel: after digest with CPB. The theoretical mass of the bispecific is 144,613.19 Da, corresponding to the major peak. Treatment with CPB results in the loss of the 144,745.26 Da peak indicating that it is a portion of the bispecific with the carboxy-terminal lysine residue still attached. (E) The K11/K48-bispecific antibody is a coincidence detector. K11/K48-branched and K11/K48-mixed ubiquitin trimers were analyzed by western blotting using the indicated antibodies. (F) The K11/K48-specific antibody preferentially detects conjugates that contain both K11-and K48-linkages. K11-linked dimers, K48-linked dimers, mixtures of K11-and K48-linked dimers, and K11/K48-branched ubiquitin trimers were analyzed by SDS-PAGE and aK11/K48-Western blot. Gel electrophoresis was performed under conditions that do not separate K11-and K48-linked ubiquitin dimers.
Supplemental Figures
(G) The K11/K48-bispecific antibody does not detect mixtures of K11-and K48-linked chains. Independent reactions were performed to produce K11-linked (''K11'') and K48-linked (''K48'') chains, and single reactions or mixtures thereof (''K11+K48'') were analyzed by western blotting using the antibodies indicated below. All blots were developed in parallel. (H) The K11/K48-bispecific antibody recognizes K11/K48-branched trimers with high affinity due to avidity from binding two linkages. Comparison of the K11/K48 bispecific, K11/gD or K48/gD control bispecifics, and monospecific gD antibodies binding to K11/K48-branched ubiquitin trimers by SPR. A representative sensogram for each antibody at 10 nM binding to immobilized branched trimer (700 RUs) is shown to illustrate the improvement in both on-and off-rates of binding due to the avidity effect. Figure S2 . Characterization of Half Antibodies and Control Bispecific Antibodies, Related to Figure 1 (A) Analytical size-exclusion analysis of the anti-K11 hole and anti-gD knob half antibodies and assembled anti-K11/gD and anti-K48/gD bispecific control antibodies. Monomer, homodimer, and heterodimer peaks are indicated and molecular weights were verified with light scattering (see Table S1 ). (B) Mass spectrometry analysis of the affinity purified anti-K11 knob, anti-K11 hole, anti-K48 hole, and anti-gD knob half antibodies. Top panel for each half antibody is in the absence of carboxypeptidase B (CPB) and the bottom panel is after digest with CPB. Red arrows in the top panels indicate a +128 Da addition to the anti-K11 knob, anti-K11 hole, and anti-gD knob half antibodies that disappears upon CPB treatment indicating that it is due to the heavy chain carboxyterminal lysine still attached to a portion of the antibodies.
